Abstract
Under the National Health Insurance system in Japan, the cancer genome core hospitals must hold expert panels (EP) which consist of multidisciplinary specialists to evaluate the indication of treatments and possibilities of secondary findings (SFs). After August 2021, serum-based cancer comprehensive genomic profiling test was also reimbursed by National Health Insurance system. This situation will increase the number of cases which must be evaluated by EP. However, some cases have obvious druggable genomic alterations or some cases have neither recommended treatment nor SFs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
